Aluminium osteomalacia in chronic renal failure patients neither on dialysis nor taking aluminium containing phosphate binders.
The incidence of aluminium osteomalacia (ALO) in patients with chronic renal failure neither on dialysis nor taking aluminium-containing phosphate binders (ACPB) is not well documented. Biochemical and histological bone investigations were performed in 35 patients fulfilling the above conditions, among whom we found an incidence of ALO of 17%. In the ALO group, salient findings were PTH level (mean +/- s.d.) of 3.1 +/- 1.4 ng/ml (normal less than 0.5 ng/ml); elevated home tap-water aluminium levels of 6.5 +/- 1.2 umol/l (normal less than 2 umol/l); and a GFR of 20.5 mls/min/1.73m, (range 2-50 mls/min/1.73m). We conclude that the aetiology of ALO in this group involves the absorption of toxic home water aluminium in the presence of an elevated PTH level and a GFR less than 50 mls/min/1.73m.
O'Brien
A A
AA
Department of Clinical Medicine, Meath Hospital, Dublin.
Moore
D P
DP
Keogh
J A
JA
D000328:Adult; D000368:Aged; D000535:Aluminum / Q000009:adverse effects* / Q000032:analysis; D001706:Biopsy; D001842:Bone and Bones / Q000032:analysis; D005260:Female; D006801:Humans; D015994:Incidence; D007494:Ireland / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010018:Osteomalacia / Q000139:chemically induced* / Q000150:complications / Q000453:epidemiology; D012307:Risk Factors; D014877:Water Pollution, Chemical / Q000009:adverse effects / Q000032:analysis
D000535:Aluminum